Stock events for Theravance Biopharma, Inc. (TBPH)
In early March 2026, the Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, causing a significant drop in TBPH's shares and leading to the termination of the ampreloxetine program. The company's Strategic Review Committee accelerated its evaluation of strategic alternatives, including a potential sale, and announced an organizational restructuring to reduce costs by approximately 60%, including a roughly 50% workforce reduction. In June 2025, the company's shares rose following the sale of Trelegy royalties.
Demand Seasonality affecting Theravance Biopharma, Inc.’s stock price
Information explicitly detailing demand seasonality for Theravance Biopharma's products and services is not readily available. YUPELRI, a treatment for COPD, has shown consistent growth and sustained demand in the U.S. market. Given that COPD is a chronic condition, significant seasonal fluctuations in demand for YUPELRI might not be a prominent factor.
Overview of Theravance Biopharma, Inc.’s business
Theravance Biopharma, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing organ-selective medicines for inflammation, immunology, and serious respiratory and neurologic conditions. Their primary commercial product is YUPELRI (revefenacin) inhalation solution, used for COPD maintenance treatment and commercialized in the U.S. through a partnership with Viatris. The company also had a late-stage investigational program for ampreloxetine, a selective norepinephrine reuptake inhibitor, in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
TBPH’s Geographic footprint
Theravance Biopharma, Inc. is incorporated in the Cayman Islands, with principal executive offices in South San Francisco, California, and corporate offices in Dublin, Ireland. The company operates through U.S. and Europe geographical segments. YUPELRI has also received regulatory approval in China, with Viatris responsible for its development and commercialization there.
TBPH Corporate Image Assessment
Theravance Biopharma's brand reputation has been negatively impacted by the failure of its Phase 3 CYPRESS study for ampreloxetine in early March 2026, leading to program termination and organizational restructuring. Prior to this, YUPELRI achieved record net sales and brand profitability in the third quarter of 2025. InvestingPro analysis in October 2025 rated Theravance Biopharma with "GREAT" financial health, and the company showed strong market performance with a 69% return over the preceding year. Analyst ratings before the ampreloxetine trial results generally indicated a "Moderate Buy" consensus, though these have since seen downgrades and price target cuts.
Ownership
Theravance Biopharma, Inc. has a high level of institutional ownership, with institutional investors holding approximately 85% to 99.10% of the stock. Major institutional owners include Madison Avenue Partners, LP, Weiss Asset Management LP, Newtyn Management, LLC, BlackRock, Inc., Irenic Capital Management LP, Vanguard Group Inc, D. E. Shaw & Co., Inc., Acadian Asset Management Llc, State Street Corp, and Arrowstreet Capital, Limited Partnership. Rick E. Winningham, the Chief Executive Officer, is also listed among the individual owners.
